title: Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome.
abstract: BACKGROUND
  End-stage liver disease due to hepatitis C virus (HCV) is the most common indication for liver transplantation in U.S. veterans. We investigated the influence of HCV genotypes on the incidence and timing of recurrent HCV hepatitis, survival, infectious morbidity, and response to interferon-alpha therapy in this unique patient population.
  
  
  METHODS
  HCV genotype was determined by direct sequencing of the NS5 region of HCV with type-specific primers.
  
  
  RESULTS
  Genotype 1a (66%, 32/47) was the predominant genotype. Type 1b was found in 25% (12/47) of patients and type 2b was found in 9% (4/47). Histopathologically recurrent HCV hepatitis developed in 53% (25/47) of the patients after transplantation. This group included 45% (14/31) of the patients with type 1a, 67% (8/12) of the patients with type 1b, and 25% (1/4) of the patients with type 2b (P>0.5). The time to recurrence and the severity of HCV recurrence as defined by aminotransferase levels or Knodell scores were not different among the three genotypes. There was a trend toward a higher incidence of major infections in patients with type 1b (75%) versus type 1a (48%) and type 2b (50%) (P=0.11). The response to interferon-a therapy did not differ significantly among the genotypes. Mortality at 5 years was 16% (5/31) in patients with genotype 1a, 42% (5/12) in patients with genotype 1b, and 50% (2/4) in patients with genotype 2b (P=0.06).
  
  
  CONCLUSIONS
  The incidence, time to recurrence, and response to interferon-alpha therapy did not differ between the various genotypes in our liver transplant recipients. However, there was a trend toward higher infectious morbidity and overall mortality in patients with genotype 1b after transplantation.
authors.affiliation: University of Pittsburgh Medical Center, Thomas E. Starzl Transplantation Institute, Falk Clinic, and the Veterans Administration Medical Center, Department of Medicine, Pennsylvania 15240, USA.
authors.forename: T
authors.initials: T
authors.lastname: Gayowski
authors.forename: N
authors.initials: N
authors.lastname: Singh
authors.forename: I R
authors.initials: IR
authors.lastname: Marino
authors.forename: H
authors.initials: H
authors.lastname: Vargas
authors.forename: M
authors.initials: M
authors.lastname: Wagener
authors.forename: C
authors.initials: C
authors.lastname: Wannstedt
authors.forename: F
authors.initials: F
authors.lastname: Morelli
authors.forename: T
authors.initials: T
authors.lastname: Laskus
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: J
authors.initials: J
authors.lastname: Rakela
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D000328:Adult; D005814:Genes, Viral / Q000502:physiology; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000209:etiology / Q000628:therapy / Q000821:virology; D006801:Humans; D015994:Incidence; D016898:Interferon-alpha / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D013530:Surgical Wound Infection / Q000453:epidemiology / Q000628:therapy / Q000821:virology; D015996:Survival Rate
chemical_list: D016898:Interferon-alpha